Ciraparantag (TFA)
Ciraparantag (PER977) TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban[1][2][3][4].
Product Specifications
CAS Number
1438492-27-3
Product Name Alternative
PER977 (TFA)
UNSPSC
12352005
Target
Factor Xa; Thrombin
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/ciraparantag-tfa.html
Solubility
10 mM in DMSO
Smiles
O=C(NCCCN1CCN(CCCNC([C@@H](N)CCCNC(N)=N)=O)CC1)[C@@H](N)CCCNC(N)=N.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Molecular Formula
C26H50F6N12O6
Molecular Weight
740.74
References & Citations
[1]Das A, et al. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol. 2015 Sep 15;4:25.|[2]Gomez-Outes A, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9 (1) :2-10.|[3]Hu TY, et al. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016 Feb 17;12:35-44.|[4]Honickel M, et al. The Reversal of Direct Oral Anticoagulants in Animal Models. Shock. 2017 Aug;48 (2) :144-158.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
AN300361P 100 µL
Recombinant Transferrin Receptor/TFRC/CD71 Monoclonal Antibody
Sign In for Pricing
View Details 
BNC041882-100 1x 100 µL
Prohibitin (Mitochondrial Marker) (PHB/1882), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC683101-500 1x 500 µL
PLK1 (Marker of Mitosis) (AZ44), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
